Tepotinib, also known as {MSC2156119|the experimental compound|this drug), represents a promising breakthrough in the management of NSCLC, particularly in individuals harboring MET duplications. This specific tyrosine https://tamzinhwex963070.blog5.net/91843778/tepotinib-a-detailed-look-into-this-agent-and-its-possibilities